A Phase I, Open-Label Study to Characterise the Absorption, Distribution, Metabolism and Excretion Following a Single Oral Dose of [14C]AZD5718 in Healthy Male Volunteers
Latest Information Update: 17 Jul 2019
At a glance
- Drugs Atuliflapon (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 25 Jun 2019 Planned End Date changed from 17 Jun 2019 to 3 Jul 2019.
- 25 Jun 2019 Planned primary completion date changed from 17 Jun 2019 to 3 Jul 2019.